Cargando…
P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009798/ http://dx.doi.org/10.1097/01.HS9.0000829592.26407.09 |
| _version_ | 1784687341971963904 |
|---|---|
| author | Dimopoulos, MA Oriol, A Nahi, H San-Miguel, J Bahlis, NJ Usmani, SZ Rabin, N Orlowski, RZ Suzuki, K Plesner, T Yoon, SS Ben Yehuda, D Richardson, PG Goldschmidt, H Reece, D Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Moreau, P |
| author_facet | Dimopoulos, MA Oriol, A Nahi, H San-Miguel, J Bahlis, NJ Usmani, SZ Rabin, N Orlowski, RZ Suzuki, K Plesner, T Yoon, SS Ben Yehuda, D Richardson, PG Goldschmidt, H Reece, D Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Moreau, P |
| author_sort | Dimopoulos, MA |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9009798 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90097982022-04-18 P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL Dimopoulos, MA Oriol, A Nahi, H San-Miguel, J Bahlis, NJ Usmani, SZ Rabin, N Orlowski, RZ Suzuki, K Plesner, T Yoon, SS Ben Yehuda, D Richardson, PG Goldschmidt, H Reece, D Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Moreau, P Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9009798/ http://dx.doi.org/10.1097/01.HS9.0000829592.26407.09 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Poster Dimopoulos, MA Oriol, A Nahi, H San-Miguel, J Bahlis, NJ Usmani, SZ Rabin, N Orlowski, RZ Suzuki, K Plesner, T Yoon, SS Ben Yehuda, D Richardson, PG Goldschmidt, H Reece, D Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Moreau, P P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL |
| title | P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL |
| title_full | P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL |
| title_fullStr | P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL |
| title_full_unstemmed | P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL |
| title_short | P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL |
| title_sort | p05: daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously treated multiple myeloma: overall survival results from the phase 3 pollux trial |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009798/ http://dx.doi.org/10.1097/01.HS9.0000829592.26407.09 |
| work_keys_str_mv | AT dimopoulosma p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT oriola p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT nahih p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT sanmiguelj p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT bahlisnj p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT usmanisz p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT rabinn p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT orlowskirz p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT suzukik p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT plesnert p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT yoonss p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT benyehudad p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT richardsonpg p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT goldschmidth p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT reeced p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT ahmadit p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT qinx p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT garvinmayow p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT gaix p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT careyj p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT carsonr p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial AT moreaup p05daratumumabpluslenalidomideanddexamethasoneversuslenalidomideanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3polluxtrial |